This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

1 (canceled).

OK to enter Tam 1/5/04

2 (currently amended). The compound according to claim 44 wherein R_1 is $N(alkyl)_2$;

R_2 is ~~-NHalkyl~~ NHalkyl; and

R_3, R_4 and R_7 are ~~-H; and~~ H.

~~R_5 is heteroalkyl.~~

3 (currently amended). The compound according to claim 44 wherein;

R_1 is a piperazine radical;

R_2 is  ; and

R_5 is ~~$-(CH_2)_2OH$~~ $(CH_2)_2OH$.

4 (currently amended). The compound according to claim 3 wherein Q is a C(=O) radical.

5 (currently amended). The compound according to claim 3 wherein Q is a C(=S) radical.

6 (currently amended). The compound according to claim 3 wherein Q is a S(=O) radical.

7 (currently amended). The compound according to claim 44 wherein;

R_1 is a piperazine radical; and

R_2 is  .

8 (currently amended). The compound according to claim 7 wherein Q is a C(=O) radical.

9 (currently amended). The compound according to claim 7 wherein Q is a C(=S) radical.

10 (currently amended). The compound according to claim 7 wherein Q is a S(=O) radical.

11 (currently amended). The compound according to claim 44 wherein;

R_1 is a piperazine radical; and

R_2 is 

12 (currently amended). The compound according to claim 11 wherein Q is a C(=O) radical.

13 (currently amended). The compound according to claim 11 wherein Q is a C(=S) radical.

14 (currently amended). The compound according to claim 11 wherein Q is a S(=O) radical.

15 (currently amended). The compound according to claim 44 wherein;

R_1 is a piperazine radical; and

R_2 is 

16 (currently amended). The compound according to claim 15 wherein Q is a C(=O) radical.

17 (currently amended). The compound according to claim 15 wherein Q is a C(=S) radical.

18 (currently amended). The compound according to claim 15 wherein Q is a S(=O) radical.

19 (currently amended). The compound according to claim 44 wherein;

R_1 is a piperazine radical; and

R_2 is  .

20 (currently amended). The compound according to claim 19 wherein Q is a C(=O) radical.

21 (currently amended). The compound according to claim 19 wherein Q is a C(=S) radical.

22 (currently amended). The compound according to claim 19 wherein Q is a S(=O) radical.

23 (currently amended). The compound according to claim 44 wherein;

R_1 is a piperazine radical; and

R_2 is  .

24 (currently amended). The compound according to claim 23 wherein Q is a C(=O) radical.

25 (currently amended). The compound according to claim 23 wherein Q is a C(=S) radical.

26 (currently amended). The compound according to claim 23 wherein Q is a S(=O) radical.

27 (currently amended). The compound according to claim 44 wherein;

R_1 is a piperazine radical; and

R_2 is  .

28 (currently amended). The compound according to claim 27 wherein Q is a C(=O) radical.

29 (currently amended). The compound according to claim 27 wherein Q is a C(=S) radical.

30 (currently amended). The compound according to claim 27 wherein Q is a S(=O) radical.

31 (currently amended). The compound according to claim 44 wherein;

R_1 is a piperazine radical; and

R_2 is  .

32 (currently amended). The compound according to claim 31 wherein Q is a C(=O) radical.

33 (currently amended). The compound according to claim 31 wherein Q is a C(=S) radical.

34 (currently amended). The compound according to claim 31 wherein Q is a S(=O) radical.

35 (currently amended). The compound of claim 44 having structure ~~Ia.~~ Ia:



Ia.

36 (currently amended). The compound of claim 44 having ~~according to the graphical representation of~~ structure Ib.



Ib

37 (previously presented). The compound of claim 44 wherein at least one stereoisomer is predominate.

38 (previously presented). A pharmaceutical composition comprising: a compound according to claim 44 and pharmaceutically acceptable salts thereof, associated with a pharmaceutically acceptable carrier, diluent, prodrug or lubricant.

39 (previously presented). A method of making compounds according to claim 44 comprising:

a) associating a compound according to structure III where A is a linker and G is N_3, with a solid support for generating an intermediate compound associated with the solid support through said linker according to structure IIIa



III

where ● is the solid support;



IIIa

b) generating the intermediate compound IIIa associated with the solid support;

c) chemically manipulating said intermediate compound thereby generating the compound according to claim 44.

40 (original). The method according to claim 39 wherein the intermediate is according to structure IV.



IV

41 (original). The method according to claim 39 wherein the solid support is a resin.

42 (previously presented). A method of using a composition or a pharmaceutically acceptable salt thereof comprising:

i) obtaining a composition according to claim 38;

ii) administering said pharmaceutical composition in a pharmaceutically acceptable manner.

43 (previously presented). The method of claim 42 wherein the pharmaceutical composition further comprises a pharmaceutically acceptable diluent, a pharmaceutically acceptable lubricant or a pharmaceutically acceptable carrier.

44 (currently amended). A compound of the formula (I):



I

where:

R_1 is $-NR_8R_9$ or $-C(R_{10})_3$;

R_2 is $-NR_{17}R_{18}$;

R_3 and R_7 each independently are $-NR_{11}R_{12}$, -YZ, alkyl, substituted alkyl, cycloalkyl, ~~heteroalkyl, substituted heteroalkyl,~~ aryl, heteroaryl, alkylenearyl, arylenealkyl, ~~alkyleneheteroalkyl,~~ halo, or H radical;

each R_5 independently is alkyl, substituted alkyl, cycloalkyl, ~~heteroalkyl,~~ heteroalkenyl, aryl, heteroaryl, $-(CH_2)_nN(R_{11}R_{12})$, $-(CH_2)_nG$ or H;

R_6 is an electron pair, alkyl, cycloalkyl, ~~heteroalkyl,~~ aryl, heteroaryl or H;

R_4, R_{11}, R_{12}, R_{15}, R_{16} and R_{17} each independently are alkyl, cycloalkyl, aryl, heteroaryl or H;

R_8 and R_9 each independently are alkyl, cycloalkyl, aryl, ~~heteroalkyl,~~ heteroaryl, H or together join to form an aminocyclic ring radical;

each R_{10} independently is alkyl, cycloalkyl, ~~heteroalkyl,~~ aryl, heteroaryl, halo or H;

R_{13} and R_{14} are each hydroxyl;

R_{18} is alkyl, cycloalkyl, aryl, ~~or~~ heteroaryl, 2-(dimethylamino)ethyl, propyl-L_1, or methyl-L_2 where L_1 is dimethylamino, 1-methylpiperazinyl, or pyrrolidinyl and L_2 is phenyl, 3,4-dimethylphenyl, 2-methylfuranyl, or cyano;

Y is a heteroatom radical with Z a radical selected from the group comprising 1 or more heteroatoms or H, alkyl, aryl, cycloalkyl, ~~heteroalkyl,~~ heteroaryl, halo, combinations thereof and adapted to fill the valence of Y, said Y being singly or doubly bound to the pyrimidine ring radical;

Q is a member selected from the group of radicals comprising $-S(=O)-$, $-S(O)_2-$, $-C(=O)-$, $-C(=S)-$, $-CH_2-$, -Y(O)- and $-C(Y)_n-$; where G is a cyclic alkyl or cyclic heteroalkyl substituent and n is an integer of at least 0; and

with the proviso that;

when R_2 is NH_2 ~~$-NH_2$~~ and R_9 is H ~~$-H$~~, then;

R_8 is not an amino acid and;

the ratio of carbon atoms to nitrogen atoms of R_5 is greater than or equal to one and;

R_{16} is H radical and;

R_{15} does not comprise a



radical.